ATNM
AMEX · Biotechnology
Actinium Pharmaceuticals Inc
$1.01
+0.01 (+1.48%)
Financial Highlights (FY 2025)
Revenue
5.34M
Net Income
-1,194,048
Gross Margin
53.0%
Profit Margin
-22.4%
Rev Growth
+5.7%
D/E Ratio
0.64
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 53.0% | 53.0% | 53.0% |
| Operating Margin | -28.1% | -29.8% | -25.4% |
| Profit Margin | -22.4% | -23.9% | -19.9% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.34M | 4.99M | 5.52M |
| Gross Profit | 2.83M | 2.65M | 2.93M |
| Operating Income | -1,501,455 | -1,486,150 | -1,401,985 |
| Net Income | -1,194,048 | -1,193,914 | -1,096,791 |
| Gross Margin | 53.0% | 53.0% | 53.0% |
| Operating Margin | -28.1% | -29.8% | -25.4% |
| Profit Margin | -22.4% | -23.9% | -19.9% |
| Rev Growth | +5.7% | +20.9% | +5.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 10.51M | 13.17M | 13.40M |
| Total Equity | 16.34M | 19.58M | 16.67M |
| D/E Ratio | 0.64 | 0.67 | 0.80 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -1,875,472 | -1,575,968 | -1,727,883 |
| Free Cash Flow | -941,082 | -691,464 | -912,603 |